Teva CRL Response For Huntington’s Drug Targeted For September
Executive Summary
Teva is on track to respond to FDA’s complete response letter for deutetrabenazine by the end of September, with a potential for approval and launch in early 2017.
You may also be interested in...
Neurocrine Eyes June Launch Date For Valbenazine In Tardive Dyskinesia
Company no longer has to worry about a US FDA advisory committee review, which the agency cancelled. Launch preparations include hiring 140 sales reps.
Teva Preps For SD-809 Tardive Dyskinesia Filing By The End Of 2016
A second Phase III study testing the VMAT2 inhibitor in the indication was positive, positioning Teva for a neck-and-neck race to market against Neurocrine.
Keeping Track: Sandoz Erelzi Is Third Biosimilar To Clear FDA; Expanded Labels For Arzerra, Blincyto
The latest drug development news and highlights from our FDA Performance Tracker.